These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 27016412

  • 1. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis.
    Liu ZG, Zhao Y, Tang J, Zhou YJ, Yang WJ, Qiu YF, Wang H.
    Oncotarget; 2016 Apr 26; 7(17):24429-35. PubMed ID: 27016412
    [Abstract] [Full Text] [Related]

  • 2. Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial.
    Huang JF, Zhang FZ, Zou QZ, Zhou LY, Yang B, Chu JJ, Yu JH, Zhang HW, Yuan XP, Tai GM, Liu FJ, Ma CC.
    Oncotarget; 2017 Jan 10; 8(2):2457-2465. PubMed ID: 27974693
    [Abstract] [Full Text] [Related]

  • 3. The addition of nimotuzumab during concurrent chemoradiotherapy improved survival outcomes in locally advanced nasopharyngeal carcinoma patients with optimal response to induction chemotherapy.
    Guo LF, Rao MY, Yu YF, Lin Q, Wu SG.
    BMC Cancer; 2024 Aug 02; 24(1):950. PubMed ID: 39095737
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of concurrent chemoradiotherapy combined with nimotuzumab for low-risk T4 stage nasopharyngeal carcinoma: A pilot study.
    Zhang S, Huang X, Zhou L, Lin S.
    Medicine (Baltimore); 2018 Sep 02; 97(38):e12503. PubMed ID: 30235761
    [Abstract] [Full Text] [Related]

  • 5. An open-label, single-arm phase II clinical study of induction chemotherapy and sequential Nimotuzumab combined with concurrent chemoradiotherapy in N3M0 stage nasopharyngeal carcinoma.
    Zhang S, Huang X, Zhou L, Wu G, Lin J, Yang S, Chen J, Lin S.
    J BUON; 2018 Sep 02; 23(6):1656-1661. PubMed ID: 30610791
    [Abstract] [Full Text] [Related]

  • 6. Concurrent nimotuzumab and intensity-modulated radiotherapy for elderly patients with locally advanced nasopharyngeal carcinoma.
    Cao C, Fang Y, Jiang F, Jin Q, Jin T, Huang S, Hu Q, Chen Y, Piao Y, Hua Y, Feng X, Chen X.
    Cancer Sci; 2024 Aug 02; 115(8):2729-2737. PubMed ID: 38806289
    [Abstract] [Full Text] [Related]

  • 7. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
    Lu Y, Chen D, Liang J, Gao J, Luo Z, Wang R, Liu W, Huang C, Ning X, Liu M, Huang H.
    BMC Cancer; 2019 Dec 30; 19(1):1262. PubMed ID: 31888551
    [Abstract] [Full Text] [Related]

  • 8. Retrospective study comparing anti-EGFR monoclonal antibody plus cisplatin-based chemoradiotherapy versus chemoradiotherapy alone for stage II-IVb nasopharyngeal carcinoma and prognostic value of EGFR and VEGF expression.
    Mao L, Tan J, Wang F, Luo Y, Liu W, Zeng F, Yu B, Huang H, Lu J, Peng X, Liu X.
    Clin Otolaryngol; 2019 Jul 30; 44(4):572-580. PubMed ID: 30972891
    [Abstract] [Full Text] [Related]

  • 9. Effect of nimotuzumab and PF induction chemotherapy combined with concurrent chemoradiotherapy in treating locally advanced nasopharyngeal carcinoma.
    Gao M, Yuan T, Zhang F.
    J BUON; 2021 Jul 30; 26(1):116-123. PubMed ID: 33721441
    [Abstract] [Full Text] [Related]

  • 10. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up.
    You R, Hua YJ, Liu YP, Yang Q, Zhang YN, Li JB, Li CF, Zou X, Yu T, Cao JY, Zhang MX, Jiang R, Sun R, Mo HY, Guo L, Cao KJ, Lin AH, Sun Y, Qian CN, Ma J, Chen MY.
    Theranostics; 2017 Jul 30; 7(8):2314-2324. PubMed ID: 28740554
    [Abstract] [Full Text] [Related]

  • 11. Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma.
    Zong JF, Liang QD, Lu QJ, Liu YH, Xu HC, Chen BJ, Guo QJ, Xu Y, Hu CR, Pan JJ, Lin SJ.
    BMC Cancer; 2021 Nov 25; 21(1):1274. PubMed ID: 34823489
    [Abstract] [Full Text] [Related]

  • 12. Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma.
    Liang R, Yang L, Zhu X.
    Cancer Control; 2021 Nov 25; 28():1073274821989301. PubMed ID: 33504193
    [Abstract] [Full Text] [Related]

  • 13. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
    Lin M, You R, Liu YP, Zhang YN, Zhang HJ, Zou X, Yang Q, Li CF, Hua YJ, Yu T, Cao JY, Li JB, Mo HY, Guo L, Lin AH, Sun Y, Qian CN, Ma J, Mai HQ, Chen MY.
    Oral Oncol; 2018 May 25; 80():1-8. PubMed ID: 29706183
    [Abstract] [Full Text] [Related]

  • 14. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
    Patil VM, Noronha V, Joshi A, Agarwal J, Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, Mahimkar M, Juvekar S, Arya S, Mahajan A, Agarwal A, Purandare N, Rangarajan V, Balaji A, Chaudhari SV, Banavali S, Kannan S, Bhattacharjee A, D'Cruz AK, Chaturvedi P, Pai PS, Chaukar D, Pantvaidya G, Nair D, Nair S, Deshmukh A, Thiagarajan S, Mathrudev V, Manjrekar A, Dhumal S, Maske K, Bhelekar AS, Nawale K, Chandrasekharan A, Pande N, Goel A, Talreja V, Simha V, Srinivas S, Swami R, Vallathol DH, Dsouza H, Shrirangwar S, Turkar S, Abraham G, Thanky AH, Patel U, Pandey MK, Prabhash K.
    Cancer; 2019 Sep 15; 125(18):3184-3197. PubMed ID: 31150120
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study.
    Lai X, Gu Q, Zheng X, Liu G, Feng W, Lin X, Mao W.
    J Cancer Res Ther; 2016 Oct 15; 12(Supplement):89-95. PubMed ID: 27721263
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma.
    Fei Z, Xu T, Li M, Chen T, Li L, Qiu X, Chen C.
    Radiat Oncol; 2020 Oct 02; 15(1):230. PubMed ID: 33008416
    [Abstract] [Full Text] [Related]

  • 19. A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial.
    de Castro Junior G, Segalla JG, de Azevedo SJ, Andrade CJ, Grabarz D, de Araújo Lima França B, Del Giglio A, Lazaretti NS, Álvares MN, Pedrini JL, Kussumoto C, de Matos Neto JN, Forones NM, Fernandes Júnior HJ, Borges G, Girotto G, da Silva IDCG, Maluf-Filho F, Skare NG.
    Eur J Cancer; 2018 Jan 02; 88():21-30. PubMed ID: 29179134
    [Abstract] [Full Text] [Related]

  • 20. Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial.
    Yuan JJ, Ding JW, Li JW, Hu RH, Gong D, Hu JL, Zhu KB, Liu Y, Ding YH, Wei JW, Zeng JL, Lu ZB, Yin WH, Ai SF, Zha GH, Zhang ZL, Zou R, Zeng L.
    BMJ Open; 2022 Aug 25; 12(8):e051594. PubMed ID: 36008072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.